Burrill and Company's Quarterly Report for Q1 2006

From Burrill and Company: Quarterly Reports: "Biotech Turns in Mixed Performance in Q1 2006 - San Francisco, CA - April 11, 2006". Too bad they seem to have stopped issuing these.

Where I have a link to the full text of these agreements in my agreement collection, I have added the link below. In the cases where the agreement has not been disclosed, I will link to a press release.

Company	Pharma/Biotech	Description	Est. Value ($M)
Trubion	Wyeth	Deal involves biopharmaceutical products to treat inflammatory disease and cancer.	800
Nastech Pharmaceuticals	Procter & Gamble Pharmaceuticals	Joint development of Nastech's parathyroid hormone (PTH1-34) nasal spray for the treatment of osteoporosis.	577
Idenix Pharmaceuticals	Novartis	Novartis licensed valopicitabine (NM283) Idenix’s lead compound for the treatment of hepatitis C.	525
SGX Pharma	Novartis	Research collaboration to develop inhibitors for chronic myelogenous leukemia.	515
Infinity Pharmaceuticals	Novartis	Alliance covers drugs targeting Bcl-2 protein family members for the treatment of a broad range of cancer indications.	400
Nuvelo	Bayer	Commercialization of alfimeprase, Nuvelo's lead Phase III product candidate, a thrombolytic.	385
Kai Pharma	Daichii Sankyo	Development of KAI-9803, with an initial focus on cardiovascular disease. KAI-9803, a delta Protein Kinase C (delta PKC) inhibitor, is a first-in-class agent for the prevention of myocardial tissue.	340
NicOx	Merck & Co.	Companies will collaborate on the development of new antihypertensive drugs.	340
Amira Pharmaceuticals	Roche	Roche will screen its compound repository against three targets and will transfer any hits to Amira. In exchange, Roche will have opt-in rights on two of the programs.	287
MethylGene	Pharmion	Development and commercialization of histone deacetylase inhibitors in North America, Europe, Middle East and certain other markets.	170